Skip to Main Content

Frequently Asked Questions

Q Who can participate in this atopic dermatitis research study?

Males or females, ages 1-80 who have active AD or who have outgrown AD. You can participate whether or not you have had problems with viral skin infections. In order to participate, you should not have any other immunological abnormality. In addition, the participant or legal guardian (if the participant is a minor) must sign an informed consent form upon learning the key facts of the study and deciding to participate.

Q Who is sponsoring this atopic dermatitis research study?

The study is sponsored by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Contract # HHSN266200400029C.

To learn more about clinical trials, please click on the following link:

http://clinicaltrials.gov/ct/info/resources

This service of the National Institute of Health and the National Library of Medicine provides general information about clinical trials,including definitions of related terminology and the process and roles related to clinical trials.

This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract No. HHSN266200400029C.

Especially Needed

Individuals with active AD or who have outgrown AD and also have a history of widespread herpes virus skin infection (also called eczema herpeticum), molluscum contagiosum (pearly wart-like skin lesions), or eczema vaccinatum (adverse reaction to smallpox vaccination).

Even though we are enrolling people regardless of race and ethnicity, we have a special need to enroll African Americans in these studies because African Americans may be at a greater risk.  This risk may be related to a different genetic background.

Where Can I Participate?

During the next five years, doctors at the following sites will be conducting clinical studies designed to make smallpox vaccinations safer for millions of people:

Please call 1-888-413-5852 if you have questions.